Even before its official nationwide debut, Nigeria is already witnessing an unusual surge in demand for Lenacapavir—a twice-yearly HIV prevention injection that could reshape how the country approaches disease control.
Across clinics and community health centres, particularly in urban hubs and high-prevalence regions, Nigerians are actively requesting the drug, pointing to a shift not just in awareness but in prevention preferences. For many already familiar with daily pre-exposure prophylaxis (PrEP), the appeal is clear: fewer doses, greater discretion, and potentially better adherence.
Developed by Gilead Sciences and endorsed by the World Health Organization in 2025, Lenacapavir represents a new frontier in HIV prevention. Its twice-yearly dosing model directly addresses one of the biggest challenges in HIV control—consistent use of preventive medication.
Public health experts say Nigeria’s early demand may reflect a deeper reality: adherence fatigue. Daily PrEP, while effective, has struggled with long-term compliance, particularly among young people and mobile populations. A long-acting injectable, they argue, could close this gap by removing the burden of daily decision-making.
The Federal Government, through the National HIV, Viral Hepatitis and STDs Control Programme, has begun a cautious rollout, distributing just over 11,500 doses so far—far short of the 52,000 anticipated in the first phase. Pilot states—including Lagos State, Kano State, Benue State and the Federal Capital Territory—were selected to reflect diverse epidemiological and demographic realities.
Yet, the early scramble for access is already exposing a familiar gap in Nigeria’s public health rollouts: demand is outpacing structured delivery.
Reports from states such as Anambra and Benue suggest that even healthcare workers—traditionally providers of such interventions—are now among those seeking access. This development, while positive in terms of awareness, raises questions about supply prioritisation and whether the most vulnerable populations will ultimately be reached first.
There are also emerging concerns about perception. Advocacy groups warn that excitement around Lenacapavir risks blurring critical distinctions between prevention and treatment. Misunderstanding its purpose could undermine its effectiveness, particularly in communities where HIV-related stigma already complicates open health-seeking behaviour.
Regulatory caution remains another key factor. The Pharmaceutical Society of Nigeria has emphasised the need for strict oversight, urging the National Agency for Food and Drug Administration and Control to complete full safety and efficacy evaluations before any mass deployment. While early global data point to minimal side effects, experts note that local monitoring will be critical in building public trust.
Beyond logistics, the rollout of Lenacapavir is also a test of Nigeria’s broader HIV strategy. With an estimated two million people living with HIV, the country remains one of the highest-burden nations globally. While infection rates have declined in recent years, progress has been uneven, particularly among key populations and in underserved regions.
In this context, Lenacapavir is more than just a new drug—it is a potential inflection point.
If successfully deployed, it could significantly reduce new infections by improving adherence and expanding prevention coverage. But if mismanaged—through limited access, weak education campaigns, or regulatory delays—it risks becoming another well-intentioned intervention that fails to reach scale.
For now, the early surge in demand offers a rare advantage: public willingness. The challenge for policymakers will be to match that enthusiasm with systems capable of delivering not just doses, but clarity, equity, and sustained impact.
